Literature DB >> 17214354

Expression of Ki-67, cyclin D1 and apoptosis markers correlated with survival in prostate cancer patients treated by radical prostatectomy.

S Aaltomaa1, V Kärjä, P Lipponen, T Isotalo, J P Kankkunen, M Talja, R Mokka.   

Abstract

OBJECTIVE: The study was designed to analyse the prognostic value of proliferation markers Ki-67 and cyclin D1 and apoptosis in prostate cancer (PC) patients treated by radical prostatectomy. PATIENTS AND METHODS: Two hundred and eleven patients treated by radical prostatectomy for localised prostate cancer were clinically followed up for a mean of 7.3 years. The primary histopathological specimens were re-analysed to ensure uniform histoplthological grading and pT classification. A tissue microarray construction (TMA) was used in immunohistochemisty to assess the expression of Ki-67, cyclin D1 and the apoptosis marker Tag. The results were analysed with light microscopy and the findings were compared to standard histology, pT and clinical follow-up data.
RESULTS: The co-expression of Ki-67 and cyclin Dl (p=0.05) was common. High fraction of Ki-67 positive cells and a high fraction of apoptotic cells were often present in same tumours (p=0.05). High apoptotic rate was related to positive surgical margin status (p=0.047). Low expression of Ki-67 was related to a low Gleason score (p<0.001), an absence of either capsule penetration (p = 0.029) or perineural invasion (p=0.004). High expression of cyclin Dl was related to perineural growth (p=0.039). Prostate specific antigen (PSA) recurrence-free survival (RFS) was predicted by Gleason grade (p<0.001) and capsule invasion (p=0.006). High expression of Ki-67 (p=0.03), as well as high apoptotic rate (p=0.04) were related to a high risk of cancer death. In multivariate analysis the seminal vesicle invasion was the only independent predictor of cancer death (p = 0.01).
CONCLUSION: The expression of Ki-67, cyclin D1 and a high apoptotic rate are related to a malignant phenotype in prostate cancer, but their prognostic value is inferior to standard histological prognostic factors.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17214354

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  18 in total

1.  Ki67 staining index and neuroendocrine differentiation aggravate adverse prognostic parameters in prostate cancer and are characterized by negligible inter-observer variability.

Authors:  Sven Gunia; Knut Albrecht; Stefan Koch; Thomas Herrmann; Thorsten Ecke; Volker Loy; Jörg Linke; Michael Siegsmund; Matthias May
Journal:  World J Urol       Date:  2008-04-05       Impact factor: 4.226

2.  Circulating Ki-67 index in plasma as a biomarker and prognostic indicator in chronic lymphocytic leukemia.

Authors:  Jean-Marie Bruey; Hagop Kantarjian; Wanlong Ma; Zeev Estrov; Chenhsiung Yeh; Amber Donahue; Heather Sanders; Susan O'Brien; Michael Keating; Maher Albitar
Journal:  Leuk Res       Date:  2010-04-01       Impact factor: 3.156

Review 3.  Tumour innervation and neurosignalling in prostate cancer.

Authors:  Brayden March; Sam Faulkner; Phillip Jobling; Allison Steigler; Alison Blatt; Jim Denham; Hubert Hondermarck
Journal:  Nat Rev Urol       Date:  2020-01-14       Impact factor: 14.432

4.  Immunohistochemical expression of minichromosome maintenance complex protein 2 predicts biochemical recurrence in prostate cancer: a tissue microarray and digital imaging analysis-based study of 428 cases.

Authors:  Antoun Toubaji; Siobhan Sutcliffe; Alcides Chaux; Kristen Lecksell; Jessica Hicks; Angelo M De Marzo; Elizabeth A Platz; George J Netto
Journal:  Hum Pathol       Date:  2012-05-02       Impact factor: 3.466

5.  Grape Powder Supplementation Attenuates Prostate Neoplasia Associated with Pten Haploinsufficiency in Mice Fed High-Fat Diet.

Authors:  Tanvi Joshi; Ishani Patel; Avinash Kumar; Virginia Donovan; Anait S Levenson
Journal:  Mol Nutr Food Res       Date:  2020-07-12       Impact factor: 5.914

6.  p53 and cyclooxygenase-2 expression are directly associated with cyclin D1 expression in radical prostatectomy specimens of patients with hormone-naïve prostate cancer.

Authors:  Panagiotis J Vlachostergios; Foteini Karasavvidou; Anna Patrikidou; Ioannis A Voutsadakis; Grigorios Kakkas; George Moutzouris; Elias Zintzaras; Danai D Daliani; Michael D Melekos; Christos N Papandreou
Journal:  Pathol Oncol Res       Date:  2011-07-23       Impact factor: 3.201

7.  Increased cancer cell proliferation in prostate cancer patients with high levels of serum folate.

Authors:  Jeffrey J Tomaszewski; Jessica L Cummings; Anil V Parwani; Rajiv Dhir; Joel B Mason; Joel B Nelson; Dean J Bacich; Denise S O'Keefe
Journal:  Prostate       Date:  2011-02-09       Impact factor: 4.104

Review 8.  Tailoring to RB: tumour suppressor status and therapeutic response.

Authors:  Erik S Knudsen; Karen E Knudsen
Journal:  Nat Rev Cancer       Date:  2008-09       Impact factor: 60.716

9.  Detection of aggressive primary prostate cancer with 11C-choline PET/CT using multimodality fusion techniques.

Authors:  Morand Piert; Hyunjin Park; Asra Khan; Javed Siddiqui; Hero Hussain; Thomas Chenevert; David Wood; Timothy Johnson; Rajal B Shah; Charles Meyer
Journal:  J Nucl Med       Date:  2009-09-16       Impact factor: 10.057

10.  Effect of low-fat diet on development of prostate cancer and Akt phosphorylation in the Hi-Myc transgenic mouse model.

Authors:  Naoko Kobayashi; R James Barnard; Jonathan Said; Jenny Hong-Gonzalez; Dan M Corman; Melvin Ku; Ngan Bao Doan; Dorina Gui; David Elashoff; Pinchas Cohen; William J Aronson
Journal:  Cancer Res       Date:  2008-04-15       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.